Skip to main content

Liver Transplant clinical trials at UCSF
10 in progress, 8 open to new patients

  • A Cohort Study of Operationally Tolerant Allograft Recipients

    open to all eligible people

    Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ. Some organ transplant recipients can stop taking anti-rejection medicines without rejecting their transplanted organ (this is called 'tolerance'). The purpose of this study will collect samples and data from 'tolerant' liver or kidney transplant recipients in order to find out: The purpose of this study is to collect samples and data in order to find out: - How long liver or kidney transplant recipients can remain tolerant; - What happens in the tolerant recipient's body over time; and - If there are patterns in the body that are linked to tolerance.

    San Francisco, California and other locations

  • Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction

    open to eligible people ages 18–70

    This research study is for liver transplant recipients and their respective living donors. The purpose of this study is: 1. To see if it is safe for liver recipients to receive one dose of donor reactive T regulatory cells (Tregs) 2. To see if the Tregs allows a liver recipient to take less, or completely stop medications normally taken after receiving an organ transplant.

    San Francisco, California and other locations

  • Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

    open to eligible people ages 21–70

    The purpose of this study is look at the safety of: - Taking a specific combination of immunosuppressant drugs after liver transplantation - Receiving one of three different doses of donor-alloantigen-reactive regulatory T cells (darTregs) while taking this specific combination of drugs

    San Francisco, California and other locations

  • Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

    open to eligible people ages 18 years and up

    The primary aim of this study is to determine whether a peripheral blood or graft lymphocyte phenotype of immune senescence or exhaustion is different between operationally tolerant and non-tolerant liver allograft recipients.

    San Francisco, California and other locations

  • Exercise Intervention in Liver Transplant Patients

    open to eligible people ages 18 years and up

    The purpose of this study is to learn more about the effects of exercise on functional status and outcomes on patients with end-stage liver disease on the liver transplant waiting list and who have undergone liver transplantation.

    San Francisco, California

  • Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

    open to eligible people ages 18 years and up

    This study is a prospective Phase IV study to determine if the use of Everolimus results in lower liver tumor recurrence and improved patient and graft survival after liver transplant for hepatocellular carcinoma (HCC). The immunosuppressive comparators will be Everolimus and Tacrolimus therapy compared to Tacrolimus and Mycophenolic acid/Mycophenolate Mofetil. Primary outcomes data is disease free survival (the time from randomization to HCC recurrence or death). Secondary outcomes are rate of recurrence of Hepatitis C, problems related to wound healing, hernia repair within the first 12 months, hepatic arterial thrombosis, renal function, acute cellular rejection, post-transplant diabetes, hypertension, and hyperlipidemia.

    San Francisco, California and other locations

  • Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre or Post Liver Transplant

    open to eligible people ages 18 years and up

    Pilot, open-label study using fixed dose combination of sofosbuvir /ledipasvir to treat HIV/HCV coinfected pre or post liver transplant participants

    San Francisco, California and other locations

  • WP01 - Normothermic Liver Preservation

    open to eligible people ages 18 years and up

    A multicenter randomized controlled trial to compare the efficacy of ex-vivo normothermic machine profusion with static cold storage in human liver transplantation.

    San Francisco, California and other locations

  • Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

    Sorry, in progress, not accepting new patients

    The purpose of this trial is to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.

    San Francisco, California and other locations

  • Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to assess the efficacy of immunosuppression withdrawal (ISW) in pediatric liver transplant (tx) recipients.

    San Francisco, California and other locations